Relative Risk of COVID-19 Reinfection by Demographic and Vaccination Factors During the Period March 2020-October 2022.
Age
Boosters
COVID-19
Primary Series
Reinfection
Vaccination
Journal
Journal of community health
ISSN: 1573-3610
Titre abrégé: J Community Health
Pays: Netherlands
ID NLM: 7600747
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
accepted:
25
10
2023
medline:
10
11
2023
pubmed:
10
11
2023
entrez:
9
11
2023
Statut:
aheadofprint
Résumé
The risk of reinfection has been difficult to quantify throughout the pandemic, making the case for COVID-19 vaccination and receipt of booster doses to the public difficult for the public health community. To address this question, Michigan statewide COVID-19 infection and vaccination data was utilized in this cross-sectional study to determine the risk of reinfection by vaccination status. Cases were divided into subgroups by vaccination status, and the risk of reinfection in the various vaccination categories was then calculated by dividing the cumulative incidence of reinfection in a vaccine category by the cumulative incidence of reinfection of those not in that category Within this population, the risk of becoming reinfected was 1.6 times higher for those who were unvaccinated than those who were vaccinated; those with a primary series saw a 27% reduced risk of reinfections compared to those without a primary series. Those with an additional booster dose had a modest improvement, with 35% reduced risk of reinfection when compared to the other groups combined. These results provide population level data to support current public health vaccination recommendations.
Identifiants
pubmed: 37945780
doi: 10.1007/s10900-023-01303-8
pii: 10.1007/s10900-023-01303-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CDC HHS
ID : NU50CK000510-01-14
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Arslan, Y., Akgul, F., Sevim, B., Varol, Z. S., & Tekin, S. (2022). Reinfection in COVID-19: Do we exaggerate our worries? European Journal of Clinical Investigation, 52(6), https://doi.org/10.1111/eci.13767 .
Bowe, B., Xie, Y., & Al-Aly, Z. (2022). Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine, 28, 2398–2405. https://doi.org/10.1038/s41591-022-02051-3 .
doi: 10.1038/s41591-022-02051-3
pubmed: 36357676
pmcid: 9671810
Silk, B. J., Scobie, H. M., Duck, W. M., et al. (2023). COVID-19 Surveillance after Expiration of the Public Health Emergency Declaration ― United States, May 11, 2023. Mmwr. Morbidity and Mortality Weekly Report, 72, 523–528. https://doi.org/10.15585/mmwr.mm7219e1 .
doi: 10.15585/mmwr.mm7219e1
pubmed: 37167154
pmcid: 10208372
Nielsen, K. F., Moustsen-Helms, I. R., Schelde, A. B., Gram, M. A., Emborg, H. D., Nielsen, J. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of alpha, Delta, or Omicron dominance: A Danish nationwide study. 2022 PLoS Med 19(11): e1004037. https://doi.org/10.1371/journal.pmed.1004037 .
Cavanaugh, A. M., Spicer, K. B., Thoroughman, D., Glick, C., & Winter, K. (2021). Reduced risk of Reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021. Mmwr. Morbidity and Mortality Weekly Report, 70, 1081–1083. https://doi.org/10.15585/mmwr.mm7032e1 .
doi: 10.15585/mmwr.mm7032e1
pubmed: 34383732
pmcid: 8360277
Interim clinical Considerations for Use of COVID-19 Vaccines in the United States (2023, June 14). CDC. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#:~ :text=COVID%2D19%20vaccination%20is%20recommended,date%20with%20COVID%2D19%20vaccination.
Thompson, M. G., Natarajan, K., Irving, S. A., et al. (2022). Effectiveness of a third dose of mRNA vaccines against COVID-19–Associated Emergency Department and Urgent Care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance — VISION network, 10 States, August 2021–January 2022. Mmwr. Morbidity and Mortality Weekly Report, 71, 139–145. https://doi.org/10.15585/mmwr.mm7104e3 .
doi: 10.15585/mmwr.mm7104e3
pubmed: 35085224
pmcid: 9351525
Surie, D., DeCuir, J., Zhu, Y., et al. (2022). Early estimates of Bivalent mRNA vaccine effectiveness in preventing COVID-19–Associated hospitalization among immunocompetent adults aged ≥ 65 years — IVY Network, 18 States, September 8–November 30, 2022. Mmwr. Morbidity and Mortality Weekly Report, 71, 1625–1630. https://doi.org/10.15585/mmwr.mm715152e2 .
doi: 10.15585/mmwr.mm715152e2
pubmed: 36580424
pmcid: 9812444